Medical treatment of pancreatic cancer
- 1 April 2007
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 7 (4) , 533-544
- https://doi.org/10.1586/14737140.7.4.533
Abstract
Pancreatic carcinoma is a devastating disease with the worst prognosis of all solid tumors; the only cure is surgery. The vast majority of patients are inoperable at the time of diagnosis and require palliative treatment. With a median survival time oscillating around 6 months, indicating an almost complete resistance to conventional cytotoxic and radiation therapy, there is ample room for improvement. Therefore, pancreatic carcinoma has been used to trial many new substances and novel concepts. All aspects of palliative antitumor treatment will be presented in detail and discussed. Finally, some outlooks are given into the future of pancreatic cancer treatment.Keywords
This publication has 99 references indexed in Scilit:
- Personal Mouse Colonies Give Hope for Pancreatic Cancer PatientsJNCI Journal of the National Cancer Institute, 2007
- An unfavourable prognosis for pancreatic cancer indicates fields of opportunityGut, 2006
- Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical marginsGut, 2006
- Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II studyBritish Journal of Cancer, 2006
- A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancerBritish Journal of Cancer, 2006
- Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trialsBritish Journal of Cancer, 2006
- Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapyNature Reviews Cancer, 2006
- The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progressionCancer Letters, 2005
- Selective anticancer drugsNature Reviews Drug Discovery, 2002
- Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with α-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trialEuropean Journal Of Cancer, 2002